Who owns Gilead Sciences (GILD)? Superinvestor holders
10 superinvestors of the 157 tracked here hold Gilead Sciences (GILD) in their latest 13F filing, with $5.3B between them. Dodge & Cox team gives it the most weight: 1.74% of the reported portfolio.
Ron Baron and Jeremy Grantham (co-founder) sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 10 of 157
- Biggest holder
- Dodge & Cox team, $3.2B
- Largest weight
- Dodge & Cox team, 1.74%of their portfolio
- Combined value
- $5.3B
- Bought last quarter
- 5
- Sold last quarter
- 7
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox teamDodge & Cox | 1.74% | $3.2B | 21.8M | ▼ Reduced 7.9% | −1.88M | Q3 2026 |
| 2 | Brandon HaleyHolocene Advisors | 0.93% | $406.4M | 3.22M | ▲ Added 23% | +605.14K | Q2 2026 |
| 3 | Josef LakonishokLSV Asset Management | 0.65% | $353.4M | 2.37M | ▼ Reduced 10% | −264.62K | Q3 2026 |
| 4 | Jim Simons (1938–2024)Renaissance Technologies | 0.42% | $306.3M | 2.05M | ▼ Reduced 7.3% | −162.54K | Q3 2026 |
| 5 | John RogersAriel Investments | 0.31% | $29.6M | 198.84K | ▲ Added 1.6% | +3.19K | Q3 2026 |
| 6 | Fred DiSantoAncora | 0.30% | $15.3M | 121.47K | ▼ Reduced 7.0% | −9.07K | Q2 2026 |
| 7 | Steve CohenPoint72 Asset Management | 0.28% | $181.6M | 1.44M | ▲ Added more than 10× | +1.43M | Q2 2026 |
| 8 | Ken GriffinCitadel Advisors | 0.25% | $439.7M | 3.48M | ▼ Reduced 13% | −501.76K | Q2 2026 |
| 9 | David Shaw (founder)D. E. Shaw & Co. | 0.18% | $289.9M | 2.29M | ▲ Added more than 10× | +2.09M | Q2 2026 |
| 10 | Ray Dalio (founder)Bridgewater Associates | 0.15% | $36.7M | 290.88K | ▲ Added 61% | +110.14K | Q2 2026 |
Sold out last quarter
- Ron Baronwas $2.3M · Q3 2026
- Jeremy Grantham (co-founder)was $2M · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 4 | 26.43M | $3.9B | 1 | 5 |
| Q2 2026 | 157 | 10 | 39.57M | $5B | 5 | 5 |
| Q1 2026 | 157 | 9 | 36.78M | $5.1B | 3 | 6 |
| Q4 2025 | 157 | 8 | 44.46M | $5.5B | 2 | 6 |
| Q3 2025 | 157 | 9 | 51.05M | $5.7B | 1 | 8 |
| Q2 2025 | 157 | 9 | 54.49M | $6B | 6 | 4 |
| Q1 2025 | 156 | 11 | 56.34M | $6.3B | 7 | 4 |
| Q4 2024 | 156 | 11 | 51.95M | $4.8B | 6 | 5 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Dodge & Cox team | 21.8M | 23.68M | 24.25M | 26.28M | 30.13M | 30.82M | 32.69M | 32.95M |
| Josef Lakonishok | 2.37M | 2.64M | 2.89M | 4.15M | 4.3M | 4.52M | 4.92M | 5.03M |
| Jim Simons (1938–2024) | 2.05M | 2.22M | 2.15M | 2.79M | 5.46M | 5.67M | 5.45M | 5.33M |
| John Rogers | 198.84K | 195.66K | 202.27K | 205.05K | 218.78K | 368.86K | 430.42K | 399.79K |
| Ken Griffin | · | 3.48M | 3.98M | 3.89M | 5.21M | 5.47M | 5.37M | 4.7M |
| Brandon Haley | · | 3.22M | 2.61M | 4.16M | 2.62M | 4.23M | 2.31M | — |
| David Shaw (founder) | · | 2.29M | — | — | — | — | — | — |
| Steve Cohen | · | 1.44M | — | — | — | — | — | 856.66K |
| Ray Dalio (founder) | · | 290.88K | 180.74K | 292.41K | 385.36K | 666.3K | 502.95K | 460.94K |
| Fred DiSanto | · | 121.47K | 130.54K | — | — | — | — | — |
| Joel Greenblatt | · | — | 375.84K | — | 345.9K | 282.2K | 250.99K | 256.04K |
| Cliff Asness | · | — | — | 2.69M | 2.38M | 2.47M | 1.86M | 1.81M |
| Israel Englander | · | — | — | — | — | — | 2.54M | — |
| Richard Pzena | — | — | — | — | — | — | 2.66K | 3.22K |
| Paul Tudor Jones | · | — | — | — | — | — | — | 162.37K |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own GILD?
In their latest 13F filings: Dodge & Cox team (1.74% of the portfolio, $3.2B), Brandon Haley (0.93% of the portfolio, $406.4M), Josef Lakonishok (0.65% of the portfolio, $353.4M), Jim Simons (1938–2024) (0.42% of the portfolio, $306.3M), John Rogers (0.31% of the portfolio, $29.6M), Fred DiSanto (0.30% of the portfolio, $15.3M), Steve Cohen (0.28% of the portfolio, $181.6M), Ken Griffin (0.25% of the portfolio, $439.7M), and 2 more.
Who bought GILD last quarter?
Brandon Haley (added 23%), John Rogers (added 1.6%), Steve Cohen (added 16,222%), David Shaw (founder) (added 1,042%), Ray Dalio (founder) (added 61%). “Last quarter” is each investor's latest reported quarter.
Who sold GILD last quarter?
Reduced: Dodge & Cox team (7.9% fewer shares), Josef Lakonishok (10% fewer shares), Jim Simons (1938–2024) (7.3% fewer shares), Fred DiSanto (7.0% fewer shares), Ken Griffin (13% fewer shares). Sold out entirely: Ron Baron (was $2.3M), Jeremy Grantham (co-founder) (was $2M).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Gilead Sciences (GILD)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/GILD/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to GILD by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.